Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
INNOVATIVE EYEWEAR INC (LUCY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$0.82-2.69%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LUCY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
improving free cash flow | A supporting condition in INNOVATIVE EYEWEAR INC's published investment case. The stated target is free cash flow yield improves to >= -0.2%. | Broken | free cash flow yield remains below -0.5% over next 4 quarters | Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established profitable compounder. The long-term thesis is developing: sales channels are expanding, while the company remains loss-making and the available evidence is too limited to judge the thesis state clearly.
The valuation model suggests LUCY is cheap versus peers, but confidence in that comparison is low. The negative expectations gap points to cautious market assumptions, and the supplied evidence does not show that those assumptions are overly pessimistic.
Near term, wholesale and international expansion has support from new launches and preliminary third-quarter sales growth, while the planned Lucyd Aero launch has no reported product-specific sales milestone. Gross profit improved modestly and net losses narrowed in the reported periods, but LUCY remains loss-making; the October 15 listing-rule notice is an added near-term risk.
Over the next year, the thesis depends on whether new channels and the planned Aero launch translate into sustained sales and better profitability. A guidance cut or further weakening in jobs data would add pressure, while continued strength from healthcare bellwethers could support the sector backdrop.
For a 1-to-3-year view, LUCY has signs of commercial progress but limited evidence of durable profit improvement, alongside high risk and a recent listing-rule concern. The long-term thesis remains uncertain and hinges on execution and loss reduction. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is improving its earnings estimates. |
| Intact |
| EPS loss worsens or remains below -1.0 USD per share in FY27 |
Diluted EPS: $-0.26 per share FY2026-Q2; GAAP. Published target: EPS loss narrows to >= -0.5 USD per share. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.26 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
annual revenue growth near 100% | A primary condition in INNOVATIVE EYEWEAR INC's published investment case. The stated target is >=99% YoY revenue growth. | Intact | YoY revenue growth falls below 70% in FY26 | Revenue growth: 74.46% FY2026-Q2; GAAP. Published target: >=99% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 202674.459023 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.42 → $-0.42 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-25 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-26 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-27 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-28 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-29 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-30 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-07-31 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-01 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-02 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-03 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-04 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-05 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-06 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-07 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-08 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-09 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-10 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-12 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-13 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-14 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-15 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-16 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-17 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-18 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-19 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-20 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-21 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-22 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-23 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-24 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-25 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-26 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-27 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-28 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-29 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-30 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-08-31 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-01 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-02 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-03 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-04 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-05 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-06 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-07 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-08 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-09 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-10 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-11 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-12 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-13 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-14 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-15 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-16 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-17 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-18 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-19 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-20 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-21 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-22 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-23 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-24 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-25 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-26 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-27 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-28 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-29 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-09-30 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-01 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-02 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-03 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-04 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-05 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-06 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-07 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-08 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-09 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-10 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-11 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-12 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-13 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-14 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-15 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-16 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-17 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-18 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-19 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-20 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-21 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-22 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-23 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-24 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-25 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-26 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-27 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-28 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-29 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-30 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-10-31 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-11-01 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-11-02 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-11-03 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-11-04 | $-0.42 | $22,000,000 | 1 / 1 |
| 2026-11-05 | $-0.42 | $22,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.